Skip Navigation

U S Department of Health and Human Services www.hhs.govOffice of Public Health and Science
WomensHealth.gov - The Federal Source for Women's Health Information Sponsored by the H H S Office on Women's Health
1-800-994-9662. TDD: 1-888-220-5446

September 19, 2008

'Healthy Fat' Chemical Aids Body's Metabolism

FRIDAY, Sept. 19 (HealthDay News) -- Scientists believe they have discovered a new class of hormones in mice, one of which may help stop or reverse obesity-related conditions such as insulin resistance and fatty liver, a new study says.

The Harvard School of Public Health researchers, whose work was published in the Sept. 19 issue of Cell, said their discovery -- if applicable to humans -- may allow the development of therapeutic or preventive treatments to counter rising obesity and resulting increases in potentially fatal metabolic disorders such as diabetes and atherosclerosis.

Lipokines, unlike other hormones which are steroid- or protein-based, were found in the fat cells of the genetically engineered mice. One of these hormones, "C16:1n7" or palmitoleate, appears to flag the muscles and liver to increase cell sensitivity to insulin and block fat accumulation in the liver. Palmitoleate also appeared to halt inflammation, a primary factor leading to metabolic disease.

The research team had noticed that genetically altered mice were remarkably resistant to the metabolic problems, like diabetes and heart disease, normally linked to a long-term, high-fat diet. In these mice, whose fat cells lacked proteins to chaperone the fat to their normal storage cells, palmitoleate production was much higher. The excess palmitoleate signaled the muscles and the liver to improve insulin function, so the cells could better absorb nutrients.

"We believe that it might be possible to chemically stimulate cells to manufacture their own 'good' fat, which could have beneficial effects on metabolism through increased palmitoleate signaling," lead researcher Gokhan Hotamisligil, a professor at the Harvard School of Public Health, said in a university news release.

If the palmitoleate effect is similar in people, Hotamisligil said it may be a potential treatment for metabolic disorders.

More information

The U.S. National Institute of Diabetes and Digestive and Kidney Diseases has more about adult obesity.

-- Kevin McKeever
SOURCE: Harvard School of Public Health, news release, Sept. 18, 2008
id=619480

Skip navigation

This site is owned and maintained by the Office on Women's Health
in the U.S. Department of Health and Human Services.

Icon for portable document format (Acrobat) files You may need to download a free PDF reader to view files marked with this icon.


Home | Site index | Contact us

Health Topics | Tools | Organizations | Publications | Statistics | News | Calendar | Campaigns | Funding Opportunities
For the Media | For Health Professionals | For Spanish Speakers (Recursos en Español)

About Us | Disclaimer | Freedom of Information Act Requests | Accessibility | Privacy

U S A dot Gov: The U.S. Government's Official Web Portal